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In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine
kinase inhibitor RG13022
HL McLeod', VG Brunton', N Eckardt', MJ Lear2, DJ Robins2, P Workman',* and
MA Grahaml't
'Cancer Research Campaign Department of Medical Oncology, University of Glasgow, Garscube Estate, Switchback Road,
Bearsden, Glasgow; 2Department of Chemistry, University of Glasgow, UK.
Summary Amplification and increased expression of many growth factor receptors, including the epidermal
growth factor receptor (EGFR), has been observed in human tumours. One therapeutic strategy for
overcoming EGF autocrine control of tumour growth is inhibition of EGFR protein tyrosine kinase (PTK). A
series of low molecular weight molecules have been identified which inhibit the EGFR PTK in vitro and
demonstrate antiproliferative activity against human cancer cell lines with high expression of EGFR. A
significant growth delay in squamous cancer xenografts has been reported for one of these compounds, the
tyrphostin RG13022. Based on these encouraging results, we sought to confirm the activity of RG13022 in vivo
and relate the effects to the in vivo plasma disposition. RG13022 and three additional peaks were detected by
HPLC following intraperitoneal administration of 20 mg kg-' RG13022 in MFl nu/nu mice. RG13022
demonstrated rapid biexponential elimination from plasma with a terminal half-life of 50.4 min. RG13022
plasma concentrations were less than 1 ,UM by 20 min post injection. A primary product was identified as the
geometrical isomer (E)-RG13022. Both RG13022 and its geometrical isomer inhibited DNA synthesis in HN5
cells after a 24 h in vitro incubation (IC50 = 11 YM and 38 gM respectively). Neither RG13022 nor its
geometrical isomer displayed significant cytotoxicity. RG13022 had no influence on the growth of HN5
tumours when administered chronically, starting either on the day of tumour inoculation or after establishment
of tumour xenografts. The rapid in vivo elimination of RG13022 has potential significance to the development
of this and other related tyrphostin tyrosine kinase inhibitors, as plasma concentrations fell below that required
for in vitro activity by 20 min post injection. The lack of in vivo tumour growth delay suggests that a more
optimal administration schedule for RG13022 would include more frequent injections or continuous
administration. An improved formulation for RG13022 is therefore required before further development of
this or other similar protein tyrosine kinase inhibitors can be made. Alternative strategies should also be sought
which display longer lasting in vivo exposures.
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The recognition that many oncogene products are involved in
growth factor cell signalling pathways and that their
constitutive activation in tumour cells is involved in the
malignant phenotype has made proteins involved in signal
transduction pathways exciting targets for the development of
novel anti-cancer agents (Aaronson, 1991; Brunton and
Workman, 1993). The diverse nature of these pathways
leads to several possible points of pharmacological interven-
tion, including interference with the phosphorylation of
regulatory proteins via specific protein kinases. Many
growth factor receptors are protein tyrosine kinases (PTKs),
in which binding of ligand results in activation via
phosphorylation of tyrosine residues on the receptor itself
and other downstream proteins (Ullrich and Schlessinger,
1990).
Amplification of growth factor receptors has been
observed for many human cancers, including epidermal
growth factor, platelet-derived growth factor, fibroblast
growth factor-I and c-erbB-2 (Aaronson, 1991; Wright et
al., 1989). Epidermal growth factor receptor (EGFR) has
been studied most thoroughly, with high expression found in
head and neck, glioma, gynaecological and breast tumours
(Harris, 1990; Mendelsohn, 1990). In vitro data suggest that
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excessive activation of EGFR results in an altered cell
phenotype, typical of malignancy (Stern et al., 1987).
Furthermore, increased EGFR expression correlates with a
poorer clinical outcome for patients with breast and ovarian
cancer (Harris, 1994; Bartlett et al., 1996). This suggests a
causal link between EGFR drive and the malignant process
in man.
Several therapeutic strategies have been implemented to
inactivate EGFR, including receptor antibodies, antisense
oligonucleotides and PTK inhibitors. Antisense oligonucleo-
tides for EGFR produced a reduction in cellular proliferation
after prolonged incubation (Chakrabarty et al., 1995; Moroni
et al., 1992). In addition, expression of antisense EGFR RNA
down-modulated the expression of EGFR and decreased
matrix invasion (Chakrabarty et al., 1995). Similar results
have been observed after in vitro incubation with monoclonal
antibodies directed against the EGFR, particularly in cell
lines bearing large numbers of receptors (Mendelsohn, 1990).
Significant growth delay or complete tumour regression has
also been observed in human tumour xenografts after
administration of EGFR monoclonal antibodies (Mendel-
sohn, 1990; Modjtahedi et al., 1993). The anti-tumour activity
was further enhanced by co-administration of conventional
cytotoxic chemotherapy (Fan et al., 1993). While antisense
oligonucleotides and monoclonal antibodies against the
EGFR show considerable promise as anti-tumour agents,
difficulties with clinical delivery of such therapy (i.e.
degradation, hypersensitivity reactions) currently restrict the
application of these approaches.
Another potential mechanism for overcoming EGF
autocrine control of tumour growth is inhibition of EGFR
PTK. A large series of low molecular weight molecules have
been identified which inhibit the EGFR PTK in vitro and
demonstrate antiproliferative activity against human cancer
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cell lines expressing high levels of EGFR (Levitzki and Gazit,
1995; Fry et al., 1994; Brunton et al., 1994; Ward et al., 1994;
Traxler et al., 1995; Workman et al., 1992). Of these
compounds, the tyrphostins have been the most extensively
studied (Levitzki and Gazit, 1995; Levitzki, 1990). Potent
tyrphostins with relative selectivity against various receptor
and oncogene PTKs have been described, including those
that inhibit EGFR in preference to the closely related c-erb-
B2 (Levitzki and Gazit, 1995). The tyrphostin RG13022 has
demonstrated inhibition of breast and squamous cell
carcinoma cell growth in vitro, inhibiting 50% of colony
formation after a 5-10 day incubation at 1-3 gLM
concentrations (Reddy et al., 1992; Yoneda et al., 1991).
EGFR autophosphorylation was inhibited at similar con-
centrations (2-5 /iM) (Reddy et al., 1992; Yoneda et al.,
1991). Significant growth delay in MH-85 squamous cancer
xenografts was observed after twice daily administration of
RG13022 200 ig i.p. for 10 days, starting 1 day after tumour
implantation (Yoneda et al., 1991). Lower doses of RG13022
failed to decrease MH-85 growth. RG13022 was reported to
have no significant activity against established MH-85
tumours (Yoneda et al., 1991).
There have been very few reports on the in vivo anti-
tumour activity of tyrosine kinase inhibitors, particularly
tyrphostins. In addition, there is little information on the in
vivo pharmacokinetics of such agents. The latter is
particularly important since it would be envisaged that a
continuous inhibition of the growth-stimulatory kinase would
be required, thus necessitating chronic administration
schedules that would deliver sustained plasma and tissue
levels.
Based on the encouraging results reported previously
(Yoneda et al., 1991), we sought to confirm the activity of
RG13022 against EGFR-expressing human tumour xeno-
grafts and characterise RG13022 in vivo pharmacokinetics.
Materials and methods
Chemicals, reagents, cell lines and animals
The tyrphostin RG13022 [(Z)-2-(3'-pyridyl)-3-(3,4-dimethox-
yphenyl)propenonitrile] and its geometric isomer [(E)-2-(3'-
pyridyl)-3-(3,4-dimethoxyphenyl)propenonitrile] were synthe-
sised in the Department of Chemistry, University of
Glasgow, by an improved method (Lear et al., submitted).
RG13022 was also obtained from Calbiochem (Nottingham,
UK) to confirm its chromatographic profile and pharmaco-
logical activity. All chemical reagents used were analytical
grade or higher (BDH, Poole, UK, or Aldrich Chemical,
Milwaukee, WI, USA). The squamous cell carcinoma cell line
HN5 was a kind gift from Dr Brad Ozanne (Beatson
Institute, Glasgow, UK) and was maintained in FIO/
Dulbecco's modified Eagle medium (DMEM) with 10%
fetal calf serum (Life Technologies, Paisley, UK). The HN5
cell line expressed 5.2 x 106 EGFR per cell (data not shown).
Athymic female nude mice (MFI nu/nu) and non-specified
mouse plasma were obtained from Harlan OLAC (Oxon,
UK). They were allowed laboratory chow and water ad
libitum and weighed between 20 g and 40 g.
In vivo activity
HN5 cells (5 x 106 in 100 pl of phosphate-buffered saline, PBS)
were injected subcutaneously into the flank of each mouse.
Starting on day 0 (day of tumour inoculation), one group of ten
mice received an intraperitoneal (i.p.) injection of RG13022
400 pg (13-20 mg kg-') daily for 21 days while a further
control group received i.p. injections of vehicle (DMSO) only.
The dose chosen was the same total daily dose administered in
the study by Yoneda et al. (1991). Twice daily drug
administration resulted in peritonitis, possibly from the
DMSO. Tumour growth was assessed by measurement across
two diameters twice weekly for 21 days after the end of
treatment. The mean diameter was used to determine tumour
volumes assuming spherical geometry (volume=r/6 x d3). The
effect of RG13022 on established HN5 tumours was also
determined. Tumour xenografts were established as described
above but treatment was delayed until the tumours had reached
a volume of 50 mm3. Treatments were then carried out as above
for a further 21 days. Mice were weighed twice weekly during
both treatment schedules.
In vivo pharmacology
The pharmacokinetic profile of RG13022 was investigated in
mice after a single i.p. injection of 20 mg kg-' in 5 ml kg-'
DMSO. Blood samples were taken by cardiac puncture under
ether anaesthesia at 0, 2, 5, 10, 15, 20, 30, 45 and 90 min post
injection. Three mice were studied per time point and plasma
was pooled and frozen at - 70°C for high-performance liquid
chromatography (HPLC) analysis.
HPLC assay
RG13022 and its associated products were analysed in mouse
plasma using reverse phase HPLC. Samples (100 pl plasma)
were extracted using protein precipitation with acetonitrile,
vortexed for 15 sec, and then centrifuged at 4500 r.p.m. for
2 min. Following direct injection of supernatant (75 pl),
separation was achieved using a ,uBondapak Phenyl pre-
column and C6 Spherisorb column (4 mm x 160 mm; 5 ,). An
isocratic mobile phase of 50% ammonium acetate buffer,
pH 3-50% methanol (v/v) was used at 1 ml min-'. Signals
were detected using a photodiode array detector scanning the
wavelengths from 250 to 400 nm (Waters Chromatographic
Division UK, Model 991). All solvents were filtered through
a 0.45 gm PTFE/propylene filter membrane (Pierce &
Warriner, USA) and degassed with helium. Calibration and
control samples of RG13022 were prepared in mouse plasma.
Isolation and identification of the main degradation product
Preliminary investigation of RG13022 in tissue culture media
and plasma observed formation of an uninidentified primary
product. To determine the structure of this primary product
(pp), it was isolated from plasma using a modified HPLC
method and fraction collection followed by lyophilisation and
identification using nuclear magnetic resonance (NMR)
spectroscopy. The HPLC mobile phase was changed to
water to avoid salt contamination of the substance after
lyophilisation and facilitate NMR spectroscopy. The
composition of the mobile phase was adjusted to 55% H20
and 45% methanol to achieve optimum separation. Signals
were detected over the range of 250 nm to 400 nm. The
quality of separation was checked by analysing contour plots.
The mobile phase fractions containing the pp were isolated
using a Waters fraction collector (Waters Chromatographic
Division, Millipore, UK). An aliquot of the collected and
pooled fractions was reanalysed under the same HPLC
conditions to determine peak purity. The collected fractions
were then lyophilised (Freeze drier Christ ALPHA, Christ,
Osterode/Harz, Germany). The isolated substance (0.2 mg)
was analysed in cadmium chloride by 'H-NMR spectrocopy
(200 MHz) using a Briiker AM200SY instrument.
Antiproliferative and cytotoxic assays
The antiproliferative activity of RG13022 and its geometrical
isomer against HN5 cells was determined in 96-well plates
seeded at 1 x 104 cells per well and maintained for 48 h. Cells
were then exposed to drug at 0.1 -1I00 M for 24 h. [3H]-
thymidine (0.1 puCi) was added to each well for the last 3 h.
Cells were washed with cold PBSx3, trypsinised and
harvested (Wallace 1295-001, Wallace Oy, Turku, Finland)
onto a glass fibre filtermat (Wallace Oy). Incorporation of
[3H]thymidine into DNA was then determined by automated
scintillation counter (Wallace 1205 BETAPLATE, Wallace
Oy) and used as a measure of growth inhibition. The
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cytotoxic activity of RG13022 and its geometrical isomer
against HN5 cells was determined in 96-well plates seeded at
1 x 103 cells per well and maintained for 48 h. Cells were then
exposed to drug at 0.1-100 M for 24 h. Cells were then
maintained in drug-free medium for 72 h, with media
replaced daily. Reduction of tetrazolium dye was determined
after addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium (MTT) to each well for 4 h, solubilised in
DMSO and glycine buffer, and measured at 570 nm (Plumb
et al., 1989). Using this protocol, the MTT assay is a measure
of cytotoxicity, as cells are allowed to recover through 2-3
cell cycles post treatment in this protocol (Plumb et al., 1989).
Results
A sensitive and precise automated HPLC assay for detection
of RG13022 and related products in mouse plasma was
developed. RG13022 in DMSO had a maximum absorbance
(A max) at 353 nm and retention time of 21 min. The
calibration curve was linear over the range 0.1 Mg ml-1 to
20 jug ml-' (r2= 0.998). The lower limit of detection was
50 ng ml-'. The assay precision, determined at 1 ,Mg ml-',
had a coefficient of variation of 6.0% (n = 10).
The plasma disposition of RG13022 and its pp were
characterised in MFI nu/nu mice. Four drug related peaks
could be detected by HPLC. The drug-related peaks appeared
at 7.4, 9.1, 13.4 and 21.3 min retention time (Figure 1). The
peak with a retention time of 21.3 min coeluted with
RG13022 and had the same spectrum. Three additional
peaks were also detected in mouse plasma following
intraperitoneal administration of 20 mg kg- ' RG13022. The
peak at 9.1 min was consistent with the pp. The peaks at 7.4
and 13.4 min were only observed in vivo and were thought to
be metabolites. The maximum concentration of RG13022 in
plasma, measured at the 2 min time point, was 6.3 Mg ml-'
(28 gM). RG13022 demonstrated rapid biexponential elimina-
tion from plasma with a clearance of 195 ml min-'kg-1 and
terminal half-life (t,, ) of 50.4 min (Figure 2). Based on the
peak areas of chromatograms taken at 340 nm wavelength,
the pp had a faster rate of elimination (terminal t lof
23.8 min). RG13022 plasma concentrations were less than
1 gM by 20 min post injection.
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It was possible to separate and isolate the pp from tissue
culture media and plasma. After lyophilisation a yellow
substance was isolated and analysed by 'H-NMR spectro-
scopy. The geometrical (E) isomer was prepared by
irradiation of RG13022 and reference spectra were obtained
(Lear et al., submitted). The pp was identified by comparison
of its spectral data with those of the (E) isomer, which were
identical. The most striking features of the NMR spectrum of
the (E) isomer were the methoxy methyl signals at different
chemical shifts of 63.48 and 3.82. In the spectrum of the (Z)
isomer (RG13022) these signals are much closer in chemical
shift at 63.89 and 3.91.
Inhibition of DNA synthesis was observed in the HN5
cells after 24h exposure to RG13022 (IC50=11.0+0.8 MM;
Figure 3a). The (E) isomer was a less potent inhibitor of 3H-
thymidine incorporation (IC50 = 38.0 + 1.8 /tM Figure 3a).
Neither RG13022 nor the geometrical isomer displayed
significant cytotoxicity, with a <10% decrease in viable
cells after 24 h incubation with 100 M (Figure 3b).
Chromatographic analysis of RG13022 in tissue culture
media demonstrated >90% stability over 24 h at 37°C. The
pp was present in tissue culture media by 3 h and reached
6% of the total tyrphostin concentration.
RG1 3022 had no influence on the growth ofHN5 squamous
tumours when administered once daily for 21 days starting on
the day of tumour inoculation or after the tumour xenografts
had grown to a volume of 50 mm3 (Figure 4). No difference in
body weight was observed for any treatment group.
Discussion
Inhibition of PTK offers a novel approach to anti-cancer
drug therapy. Altering the cellular signalling response to
receptor activation would provide a mechanism for slowing
tumour growth and complement conventional, DNA-directed
chemotherapy (Workman et al., 1992). In particular, the
tyrphostin class of PTK inhibitors have shown great promise
in in vitro antiproliferative and receptor phosphorylation
studies (Levitzki and Gazit, 1995; Levitzki, 1990). The
reversible nature of receptor tyrosine kinase inhibition may
necessitate frequent drug administration schedules to achieve
a continuous inhibition of the growth-factor stimulated
proliferation. Therefore, in vivo characterisation of tyrphos-
tin disposition is required to design schedules that would
deliver sustained plasma and tissue levels. This report is the
first to characterise the in vivo disposition of a tyrphostin
PTK inhibitor.
RG13022 was rapidly absorbed after injection and was
detectable at the earliest measured time point (2 min). The
10
RG 13022
E
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Figure 1 High-performance liquid chromatogram of pretreat-
ment plasma (a) and that taken 20min after an intraperitoneal
injection of RG13022 20mgkg-1 (b).
0.1
0
0 10 20 30 40 50 60 70 80 90 100
Time (min)
Figure 2 The concentration-time profile of RG13022 after a
single intraperitoneal injection of 20mgkg-1 in MFl nu/nu mice.
Each data point represents the pooled sample from three mice.
4
r.
1
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rapid absorption could be due to the hydrophobic nature and
low molecular weight of the compound and may be influenced
by the vehicle (DMSO). The peak plasma level was
6.34 ,ug ml-' or 28 gM. This concentration is 2.5-fold higher
than the IC50 of RG13022-associated inhibition of HN5 DNA
synthesis after a 24 h incubation. The concentrations needed
for in vivo activity of tyrphostins are not known. It has been
reported that IC5s values for the antiproliferative activity of
tyrphostins in whole organ culture are 5-10 times higher than
in cell culture (Dvir et al., 1991). Nevertheless, our results,
together with the report of RG13022 in vivo activity, indicate
that pharmacologically relevant concentrations are achievable
in vivo (Yoneda et al., 1991). The terminal half-life of RG13022,
determined from plasma samples measured over 90 min, was
estimated to be 50.4 min. Although optimum assessment of
terminal elimination is made after drug measurement over a 4-
5 half-life time interval, RG13022 was not detectable in plasma
by 2 h post injection. Therefore, it is unlikely that sufficient
quantity of drug was present for continuous inhibition of
receptor tyrosine kinase activity. However, caution should be
applied with the extrapolation of plasma tyrphostin exposure
as a surrogate marker of tumour exposure. The pharmacoki-
netic profile of tumour RG13022 is not known as tissue levels
were not evaluated.
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Together with RG13022, three other drug-related sub-
stances were observed, with the largest peak eluting at 9 min.
No standards were available, and therefore these substances
could not be quantified. One of these drug-related substances
showed the chromatographic and spectral characteristics of
the pp. Extensive NMR spectroscopy and chromatographic
analysis identified the pp as the (E) isomer of RG13022. The
product was rapidly formed in vivo and had a terminal t,, of
23.9min. It is not possible to deduce from these data if the
formation of this substance in vivo occurred before the
absorption of the parent drug from the peritoneum or within
the plasma. The pp was not detectable in the drug solution
used for in vivo studies. The plasma profiles of the two other
drug-related peaks reflected the production of metabolites.
An initial increase in plasma concentration of these
metabolites was followed by a biexponential decline.
Formation of these substances before absorption, followed
by a slower absorption profile than RG13022, is also
possible. However, substances with similar chromatographic
and spectral characteristics were not seen in vitro experiments
(unpublished observations).
Yoneda et al. (1991) mentioned that RG13022 undergoes
light-induced isomerisation, but assumed that the two
isomeric forms were equally active. This contrasts with the
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Figure 3 Inhibition of (a) [3H]thymidine incorporation and (b)
cytotoxicity of RG13022 (0) and its (E) isomer (0) in HN5 cells
after 24 h incubation.
Time (days)
Figure 4 The influence of RG13022 on in vivo growth of HN5
xenografts following 400kg daily for 21 days after (a) the
implantation of tumour or (b) tumours had reached a volume of
50mm3. *, RG13022; O, vehicle.
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results of the current work, in which the (E) isomer was
found to be one third as potent as the (Z) isomer (RG1 3022)
inhibiting HN5 DNA synthesis after 24 h in vitro incubation.
Therefore, evaluation of RG13022 disposition alone will give
an underestimate of the agent's systemic exposure.
In contrast to the findings of Yoneda et al. (1991), RG1 3022
demonstrated no anti-tumour activity against human tumour
xenografts in the current study. The absence of tumour growth
suppression was found when RG 13022 was administered
chronically for 21 days from the day of tumour inoculation
or after tumour establishment had occurred. Although both
studies used squamous cell carcinoma cell lines with high levels
of EGFR, differences in cell signalling, downstream targets or
death pathways between the cell lines may contribute greatly to
the in vivo activity of RG13022 previously described
(Modjtahedi et al., 1993; Yoneda et al., 1991), However,
previous studies have demonstrated in vivo inhibition of HN5
tumour growth by EGFR antibodies (Modjtahedi et al., 1993).
This demonstrates that HN5 cells are susceptible to growth
inhibition by targeting the-EGFR. An additional difference
between the study of Yoneda et al. (1991) and the current study
was the drug administration schedule. Yoneda et al. 1991
administered RG 13022 at 200 ,ug per mouse twice daily (400 ,ug
total dose), whereas in the current study we administered the
same dose as a single daily injection. The rapid elimination of
RG13022 resulted in plasma concentrations <1 ,IM by 20 min
after injection. The rate of drug degradation of other tyrphostin
compounds has also been shown to influence the degree of in
vitro PTK inhibitory activity against pp6oc-src and EGFR
(Ramdas et al., 1994). The antiproliferative activity of
RG13022 has an IC50 of 2-20 giM against human cancer cell
lines after prolonged (> 16 h) in vitro incubations (data not
shown) (Reddy et al,, 1992; Yoneda et al., 1991). In addition,
although RG1 3022 had potent inhibitory activity against HN5
fell DNA synthesis, little cytotoxic activity was observed for
either RG13022 or its geometric isomer. This suggests that a
better administration schedule for RG13022 would include
frequent injections or continuous administration. In the current
study twice daily administration of RG13022 was not tolerated
by the MFl nu/nu mice because of the toxicity of the DMSO
drug vehicle (data not shown). An improved formulation for
RG13022 is therefore required before the in vivo activity of this
PTK inhibitor can be assessed further. The results also
highlight the need to develop more water-soluble tyrosine
kinase inhibitors that give sustained plasma and tissue
exposures, as continuous blockage of the tyrosine kinase
signal is likely to be required for growth inhibition.
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